Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to keep blood pressure in check after hospital discharge

NCT ID NCT07511361

Disease control Sponsor: Kardigan, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 5 times

Summary

This study tests a drug called tonlamarsen in adults who were recently hospitalized for dangerously high blood pressure. Participants receive either the drug or a placebo as a shot under the skin every 4 weeks. The goal is to see if tonlamarsen can lower blood pressure and reduce a protein linked to hypertension, helping patients stay healthy after leaving the hospital.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tonlamarsen
What this could lead to
If it works, this could provide a new treatment option to help control blood pressure after a severe hypertensive episode, potentially reducing the risk of future hospitalizations.
What could go wrong
This is an early Phase 2b trial with only 100 participants, so results may not apply to everyone. The drug may not lower blood pressure significantly or could have side effects.
Why investors are watching

Kardigan is a micro-cap company, so a single late-stage trial can define its value. This phase 2b study tests whether tonlamarsen lowers blood pressure in 140 adults who recently left the hospital after a severe hypertension episode. A clear result would tell investors whether the drug works in a high-risk patient group, which matters more for a small company than for a large one.

If it works: A positive result could position tonlamarsen as a viable treatment for acute severe hypertension, giving Kardigan a lead asset to advance toward later trials. That outcome might attract partnership interest or funding to support further development.

If it fails: The trial could fail to show a meaningful blood pressure reduction, or safety issues could emerge, which would likely end the drug's development. Trials at this stage often fail, and for a micro-cap company, a negative readout could leave Kardigan without a clear path forward.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2 * Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization * At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg * Presence of established cardiovascular or renal disease Key Exclusion Criteria: * Has known history of secondary hypertension * Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated) * Has abnormal thyroid function with clinical significance * Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening * History of and/or obvious clinical signs or symptoms of cirrhosis or other significant liver disease * Alanine aminotransferase or aspartate aminotransferase \>2 x upper limit of normal * Most recent hospitalization was for non-cardiovascular or non-renal conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute severe hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypertensive Crisis hypertensive disorder hypertensive urgency malignant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute severe hypertension Hypertension Hypertensive emergency Hypertensive urgency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor Scott and White Research Institute - Temple

    RECRUITING

    Temple, Texas, 76502, United States

  • Chattanooga Research & Medicine CHARM

    RECRUITING

    Chattanooga, Tennessee, 37404, United States

  • Eagle Clinical Research

    RECRUITING

    Chicago, Illinois, 60621, United States

  • Homestead Associates in Research

    RECRUITING

    Homestead, Florida, 33033, United States

  • Laguna Clinical Research Associates

    RECRUITING

    Laredo, Texas, 78041, United States

  • OnSite Clinical Solutions, LLC

    RECRUITING

    Fort Mill, South Carolina, 29715, United States

  • Progressive Medical Research

    RECRUITING

    Port Orange, Florida, 32127, United States

  • Research Innovations, LLC

    RECRUITING

    Beavercreek, Ohio, 05431, United States

  • Richmond University Medical Center (RUMC)

    RECRUITING

    Staten Island, New York, 10310, United States

  • Tapia Internal Medicine Clinic

    RECRUITING

    Paris, Texas, 75460, United States

  • Western Nephrology and Metabolic Bone Disease, PC - Arvada

    RECRUITING

    Arvada, Colorado, 80002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.